DOI:
10.1055/s-00000011
DMW - Deutsche Medizinische Wochenschrift
LinksClose Window
References
Bendell JC, CE A, Andre T. et al.
Efficacy and tolerability in an open-label phase I/II study of MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in combination in patients (pts) with BRAF V600E mutated colorectal cancer (CRC).
J Clin Oncol 2014;
32: 5s
Search in:
We do not assume any responsibility for the contents of the web pages of other providers.